Clinical Trials Logo

Coronary Artery Bypass Surgery clinical trials

View clinical trials related to Coronary Artery Bypass Surgery.

Filter by:

NCT ID: NCT00242697 Completed - Clinical trials for Coronary Artery Disease

Double-Blind Comparison of Combined General-Spinal Anesthesia to General Anesthesia for Coronary Artery Surgery

Start date: April 2002
Phase: Phase 3
Study type: Interventional

Use of neuraxial agents in anesthesia for cardiac surgery is expanding. We have used combined general-spinal anesthesia for cardiac surgery for 12 years. We hypothesized that compared to general anesthesia, the combined techniques would provide comparable intraoperative hemodynamics and improved postoperative analgesia. This study subjected these techniques to a double-blind randomized trial.

NCT ID: NCT00209521 Completed - Clinical trials for Coronary Artery Bypass Surgery

Comparison of AQUAVAN® Injection to DISOPRIVAN® Injectable Emulsion for Anesthesia During Coronary Artery Surgery

Start date: June 2002
Phase: Phase 2
Study type: Interventional

This is an exploratory clinical trial designed to examine the efficacy, safety and tolerability of fospropofol (AQUAVAN) Injection compared to propofol (DISOPRIVAN) Injectable Emulsion when used to preoperatively sedate, induce, and maintain general anesthesia and to postoperatively sedate patients undergoing elective coronary artery surgery.

NCT ID: NCT00079586 Completed - Clinical trials for Cardiovascular Disease

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

Start date: April 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.

NCT ID: NCT00079508 Completed - Clinical trials for Cardiovascular Disease

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

HIT/TS
Start date: April 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) Type II undergoing cardiac surgery on cardiopulmonary bypass (CPB), Angiomax is a safe and effective anticoagulant.

NCT ID: NCT00073593 Completed - Cardiac Surgery Clinical Trials

Comparing Angiomax to Heparin With Protamine Reversal in Patients OPCAB

OPCAB
Start date: August 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to examine the safety and efficacy of Angiomax as an alternative anticoagulant to heparin with protamine reversal in patients undergoing off-pump coronary artery bypass graft surgery.

NCT ID: NCT00073580 Completed - Thrombosis Clinical Trials

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

Start date: October 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to examine the safety and efficacy of Angiomax as an anticoagulation in patients with heparin-induced thrombocytopenia (HIT)/heparin-induced thrombocytopenia with thrombosis syndrome (HITTS) undergoing off-pump coronary artery bypass (OPCAB) surgery.